Under surveillance
Multi-million-dollar fines are the outcome for firms found to be violating trade surveillance rules and as regulators make robust recordkeeping and data management a priority, OTC market players need to do the same. Poor recordkeeping can be an expensive business. In February 2024 alone, the US Securities and Exchange Commission (SEC) handed out a total of US$81 million in fines to 16 firms comprising broker-dealers and advisers for “for widespread and longstanding failures by the firms and their employees to maintain and preserve electronic communications”.[1] In the same month, FINRA, a self-regulatory government-authorised not-for-profit organisation that oversees US broker-dealers, hit a major US investment bank with a US$ 512,000 penalty for “gaps in its surveillance reports” which meant the bank “could not perform reasonable supervisory reviews of trading activity in warrants, rights, units, and certain over the counter (OTC) equity securities for potential manipulation”.2 These considerable financial punishments send a clear message to the sector that data management and recordkeeping is of paramount importance to the regulators.
And as 2024 heralds new trade reporting requirements across several major jurisdictions – including the Unique Product Identifier (UPI) to provide a globally consistent product taxonomy; the Unique Transaction identifier (UTI) which requires common transaction identifiers across reporting regimes; the Critical Data Elements (CDE) to provide internationally harmonised data fields and definitions, and ISO 20022 XML messaging standards for reporting to trade repositories – market players can expect even more scrutiny.
Improving surveillance
Alongside paying out significant fines, the firms punished by the SEC also agreed to retain independent compliance consultants to “among other things, conduct comprehensive reviews of their policies and procedures relating to the retention of electronic communications found on personal devices and their respective frameworks for addressing non-compliance by their employees with those policies and procedures”.3
Meanwhile, the bank fined by FINRA has since added the missing securities to the surveillance reports either in response to regulator’s investigation or through the firm’s adoption of new surveillance reports.4
While appointing third-party specialists and moving to new surveillance processes to help identify data and recordkeeping failures may have come a little too late for these institutions, other OTC market players can avoid falling foul of the regulators by getting surveillance systems up to speed.
Effective surveillance systems rely on quality, consistent and harmonised data. Collaboration is key to improving security, and market participants need to share data with one another, and with regulators, to identify potential violations more efficiently and mitigate market abuse.
This means employing systems that are capable of processing vast amounts of data in real-time, and that can identify patterns and detect potential violations more accurately.
Access to data
Parameta Solutions, the data and analytics division of TP ICAP Group, the world’s largest inter-dealer broker, has unparalleled access to data to support compliance professionals.
We offer visibility into bid and ask prices, full order lifecycle, trade volumes and transaction details which can support clients' risk assessment and market abuse monitoring requirements.
Our data is collated across TP ICAP venues into a curated and normalised feed, with industry-standard taxonomy and nomenclature. Raw order and trade data is further enriched to give deeper insights into the activity and nature of OTC markets.
The curated data can be integrated with incumbent compliance and surveillance systems providing timely and consistent data that adheres to the regulatory regimes across the globe.
It is clear that no institution is immune from the wrath of the regulator where violations occur, but likelihood of violations can be reduced with the right systems in place.
To find out more…
Bibliography
[2] finra.org 2019063499505 Goldman Sachs & Co. LLC CRD 361 AWC lp
[4] finra.org 2019063499505 Goldman Sachs & Co. LLC CRD 361 AWC lp
© 2024 ICAP Information Services Limited (“IISL”). This communication is provided by ICAP Information Services Limited or a member of its group (“Parameta”) and all information contained in or attached hereto (the “Information”) is for information purposes only and is confidential. Access to the Information by anyone other than the intended recipient is unauthorised without Parameta’s prior written approval. The Information may not be not used or disclosed for any purpose without Parameta’s prior written approval, including without limitation, storing, copying, distributing, licensing, selling or displaying the Information, using the Information in an application or to create derived data of any kind, co-mingling the Information with any other data or using the data for any unlawful purpose of for any purpose that would cause it to become a benchmark under any law, regulation or guidance.
The Information is not, and should not be construed as, a live price, an offer, bid, recommendation or solicitation in relation to any financial instrument or investment or to participate in any particular trading strategy or constituting financial or investment advice or a financial promotion. The Information is not to be relied upon for any purpose whatsoever and is provided “as is” without warranty of any kind, either expressly or by implication, including without limitation as to completeness, timeliness, accuracy, continuity, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed, to the fullest extent possible under applicable law. In no circumstances will Parameta be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. Parameta may suspend, withdraw or modify or change the terms of the provision of the Information at any time in its sole discretion, without notice.
All rights, including without limitation intellectual property rights, in and to the Information are, and shall remain, the property of IISL or its licensors. Use of, access to or delivery of Parameta’s products and/or services requires a prior written licence from Parameta or its relevant affiliates. The terms of this disclaimer are governed by the laws of England and Wales.